|Day Low/High||54.29 / 55.71|
|52 Wk Low/High||24.75 / 77.10|
Board members who sit on four or more boards may find it impossible to manage their time when faced with an insurgent investor or merger situation -- or both.
The drug maker with an osteoporosis product in development has been speculated about as a consolidation candidate.
ASBMR Meeting to include an oral late-breaking presentation of the results of the clinical development of an optimized abaloparatide transdermal patch
Cramer says don't buy Tesaro but do buy Cirrus Logic.
Cramer says discipline is needed to start trimming positions and taking profits.
Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.
- Data demonstrate that abaloparatide-SC reduced the risk of osteoporotic fractures and increased bone mineral density across a broad group of postmenopausal women with osteoporosis regardless of baseline characteristics -
Radius Health and Seres Therapeutics have something in common, Cramer says -- both are great biotechs being dragged down by the current market.
When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says
Cramer loves Bristol-Myers and he's not betting against Goldman Sachs.
There are many low-value stocks that never should've gotten that low in the first place, Cramer says.
Cantor Fitzgerald lowered its price target on Radius Health (RDUS) stock to reflect lower biotechnology valuations in the current market environment.